✦ LIBER ✦

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases : A double-blind, randomized dose–response study

✍ Scribed by James R. Berenson; Lee S. Rosen; Anthony Howell; Lester Porter; Robert E. Coleman; Walter Morley; Robert Dreicer; Steven A. Kuross; Allan Lipton; John J. Seaman

Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 118 KB
Volume: 91
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(20010401)91:7<1191::aid-cncr1119>3.0.co;2-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term efficacy and safety of zoledro

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors : A randomized, Phase III, double-blind, placebo-controlled trial

✍ Lee S. Rosen; David Gordon; N. Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB 👁 2 views

Long-term efficacy and safety of zoledro

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma : A randomized, double-blind, multicenter, comparative trial

✍ Lee S. Rosen; David Gordon; Mary Kaminski; Anthony Howell; Andrew Belch; John Ma 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

## Abstract ## BACKGROUND The goal of the current study was to compare the long‐term (25‐month) safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or multiple myeloma. ## METHODS Patients (__n__ = 1648) were randomized to